Red blood cell transfusion burden by day 30 predicts mortality in adults after single-unit cord blood transplantation.


Journal

Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459

Informations de publication

Date de publication:
11 2019
Historique:
received: 13 02 2019
accepted: 17 04 2019
revised: 12 04 2019
pubmed: 16 5 2019
medline: 18 9 2020
entrez: 16 5 2019
Statut: ppublish

Résumé

Increased red blood cell (RBC) transfusion requirements are associated with morbidity and mortality after allogeneic hematopoietic cell transplantation. However, its impact on the outcomes after cord blood transplantation (CBT) is unclear. We retrospectively analyzed the data of 278 adult patients who received single-unit CBT in our institute. The median number of RBC transfusions for each patient was 12 units (range, 4-66) by day 30 and 14 units (range, 4-70) by RBC engraftment. Sex, cord blood CD34

Identifiants

pubmed: 31089286
doi: 10.1038/s41409-019-0555-8
pii: 10.1038/s41409-019-0555-8
doi:

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1836-1846

Commentaires et corrections

Type : CommentIn

Références

Liu C, Grossman BJ. Red blood cell transfusion for hematologic disorders. Hematol Am Soc Hematol Educ Program. 2015;2015:454–61.
doi: 10.1182/asheducation-2015.1.454
Xenocostas A, Yee A, Wong CJ, Sutton DM, Lipton JH, Kiss TL, et al. RBC transfusion requirements after allogeneic marrow transplantation: impact of the before-transplant Hb level on transfusion and early survival. Transfusion. 2003;43:373–82.
doi: 10.1046/j.1537-2995.2003.00339.x
Vande Vusse LK, Madtes DK, Guthrie KA, Gernsheimer TB, Curtis JR, Watkins TR. The association between red blood cell and platelet transfusion and subsequently developing idiopathic pneumonia syndrome after hematopoietic stem cell transplantation. Transfusion. 2014;54:1071–80.
doi: 10.1111/trf.12396
Hosoba S, Waller EK, Shenvi N, Graiser M, Easley KA, Al-Kadhimi Z, et al. Peritransplantation red blood cell transfusion is associated with increased risk of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24:973–82.
doi: 10.1016/j.bbmt.2018.01.003
Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104:3813–20.
doi: 10.1182/blood-2004-03-1001
Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109:1322–30.
doi: 10.1182/blood-2006-04-020172
Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653–60.
doi: 10.1016/S1470-2045(10)70127-3
Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, et al. Comparison of outcomes of 8/8 and 7/8 allele-matched unrelated bone marrow transplantation and single-unit cord blood transplantation in adults with acute leukemia. Biol Blood Marrow Transplant. 2016;22:330–8.
doi: 10.1016/j.bbmt.2015.10.006
Konuma T, Tsukada N, Kanda J, Uchida N, Ohno Y, Miyakoshi S, et al. Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. Am J Hematol. 2016;91:E284–92.
doi: 10.1002/ajh.24340
Tanoue S, Konuma T, Kato S, Oiwa-Monna M, Isobe M, Jimbo K, et al. Platelet transfusion refractoriness in single-unit cord blood transplantation for adults: Risk factors and clinical outcomes. Biol Blood Marrow Transplant. 2018;24:1873–80.
doi: 10.1016/j.bbmt.2018.05.006
Konuma T, Kato S, Oiwa-Monna M, Tanoue S, Ogawa M, Isobe M, et al. Cryopreserved CD34
doi: 10.1016/j.bbmt.2017.03.036
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.
Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–9.
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.
doi: 10.1182/blood-2014-01-552984
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.
doi: 10.1038/bmt.2012.244
Konuma T, Kato S, Ooi J, Oiwa-Monna M, Ebihara Y, Mochizuki S, et al. Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission. Biol Blood Marrow Transplant. 2014;20:396–401.
doi: 10.1016/j.bbmt.2013.12.555
Konuma T, Kato S, Oiwa-Monna M, Tojo A, Takahashi S. Single-unit cord blood transplant for acute lymphoblastic leukemia and lymphoma using an intensified conditioning regimen of total body irradiation, high-dose cytarabine and cyclophosphamide. Leuk Lymphoma. 2015;56:1148–50.
doi: 10.3109/10428194.2014.949261
Kekre N, Christou G, Mallick R, Tokessy M, Tinmouth A, Tay J, et al. Factors associated with the avoidance of red blood cell transfusion after hematopoietic stem cell transplantation. Transfusion. 2012;52:2049–54.
doi: 10.1111/j.1537-2995.2011.03552.x
Liesveld J, Pawlowski J, Chen R, Hyrien O, Debolt J, Becker M, et al. Clinical factors affecting engraftment and transfusion needs in SCT: a single-center retrospective analysis. Bone Marrow Transplant. 2013;48:691–7.
doi: 10.1038/bmt.2012.194
Le Viellez A, P’Ng S, Buffery S, Wright M, Cooney J, Cannell P, et al. Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation. Intern Med J. 2015;45:1286–92.
doi: 10.1111/imj.12894
Griffith LM, VanRaden M, Barrett AJ, Childs RW, Fowler DH, Kang EM, et al. Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993–2010): factors that predict intensity and time to transfusion independence. Transfusion. 2019;59:303–15.
doi: 10.1111/trf.14966
Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood. 2001;98:3584–8.
doi: 10.1182/blood.V98.13.3584
Wang Z, Sorror ML, Leisenring W, Schoch G, Maloney DG, Sandmaier BM, et al. The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation. Br J Haematol. 2010;149:101–10.
doi: 10.1111/j.1365-2141.2009.08073.x
Solh M, Brunstein C, Morgan S, Weisdorf D. Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants. Biol Blood Marrow Transplant. 2011;17:710–6.
doi: 10.1016/j.bbmt.2010.08.017
Booth GS, Gehrie EA, Bolan CD, Savani BN. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:1152–8.
doi: 10.1016/j.bbmt.2013.03.018
Rowley SD, Donato ML, Bhattacharyya P. Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2011;46:1167–85.
doi: 10.1038/bmt.2011.135
Tomonari A, Takahashi S, Ooi J, Tsukada N, Konuma T, Kobayashi T, et al. Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan. Bone Marrow Transplant. 2007;40:523–8.
doi: 10.1038/sj.bmt.1705765
Solves P, Carpio N, Carretero C, Lorenzo JI, Sanz J, Gómez I, et al. ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation. Bone Marrow Transplant. 2017;52:394–9.
doi: 10.1038/bmt.2016.264
Romee R, Weisdorf DJ, Brunstein C, Wagner JE, Cao Q, Blazar BR, et al. Impact of ABO-mismatch on risk of GVHD after umbilical cord blood transplantation. Bone Marrow Transplant. 2013;48:1046–9.
doi: 10.1038/bmt.2013.8
Konuma T, Kato S, Ooi J, Oiwa-Monna M, Ebihara Y, Mochizuki S, et al. Effect of ABO blood group incompatibility on the outcome of single-unit cord blood transplantation after myeloablative conditioning. Biol Blood Marrow Transplant. 2014;20:577–81.
doi: 10.1016/j.bbmt.2013.12.563
Tay J, Allan DS, Chatelain E, Coyle D, Elemary M, Petrcich W, et al. Transfusion of red cells in hematopoietic stem cell transplantation (TRIST Study): a randomized controlled trial evaluating 2 red cell transfusion thresholds. Blood. 2016;128:1032.
doi: 10.1182/blood.V128.22.1032.1032

Auteurs

Takaaki Konuma (T)

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. tkonuma@ims.u-tokyo.ac.jp.

Maki Oiwa-Monna (M)

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Mai Mizusawa (M)

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Masamichi Isobe (M)

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Seiko Kato (S)

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Tokiko Nagamura-Inoue (T)

Department of Cell Processing and Transfusion, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Satoshi Takahashi (S)

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Arinobu Tojo (A)

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH